, GT Communications, Shrewsbury, UK

• British Journal of Diabetes Vol. 16 No. 2 (2016) - Meeting Reports
  This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes
  Abstract  HTML  PDF